Baricitinib Has Better Safety Profile Than Dexamethasone When Added to Remdesivir for COVID-19 Baricitinib Has Better Safety Profile Than Dexamethasone When Added to Remdesivir for COVID-19

For patients with severe COVID-19 requiring supplemental oxygen, combining remdesivir with either baricitinib or dexamethasone led to similar survival rates off mechanical ventilation by day 29, but dexamethasone was associated with significantly more side effects, in the ACTT-4 randomized controlled trial.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news